Investor Presentation H1 2023

53 Investor presentation First six months of 2023 Novo Nordisk global insulin market leadership at 45.7% and the global insulin volume market declined by 1.9% North America Operations Market growth: -3.0% MS: 37.9% MS gain/loss': -0.5%-p Sales growth: -25% USA Market growth: -3.2% MS: 37.5% MS gain/loss': -0.3%-p Sales growth: -26% Global Market growth: -1.9% MS 45.7% MS gain/loss: -1.4%-p Sales growth: -7% EMEA Market growth: -4.0% MS: 47.1% ROW MS gain/loss¹: -0.8%-p Sales growth: -1% Market growth: -4.0% MS: 57.8% MS gain/loss: 0.7%-p Sales growth: 9% Source: IQVIA MAT, May 2023 volume figures Note: Sales growth for first six months of 2023 at constant exchange rates; Market shares are for Novo Nordisk, market growth for total insulin market 1MS gain/loss compared with May 2022 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; RoW: Asia Pacific; Latin America; MS: Market Share; Region China covers Mainland China, Taiwan, and Hong Kong Novo NordiskⓇ International Operations Market growth: -1.5% MS: 48.5% MS gain/loss: -1.8%-p Sales growth: -2% Region China Market growth: 9.6% MS: 43.3% MS gain/loss¹: -7.1%-p Sales growth: -11%

View entire presentation